Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

65.45 -0.06 (-0.09%)
Streaming Delayed Price Updated: 2:59 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way
Sierra Oncology spent just $3 million up front to acquire momelotinib. 
Via Investor's Business Daily
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) for non-hospitalized adult and adolescent patients at high risk of progression to... 
Via Benzinga
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Gilead Policy Papers Show Pandemic's Impact on HIV Prevention and Care
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Key Takeaways Everest has signed a global licensing deal for an anti-viral Covid treatment being developed by Singapore’s Experimental Drug Development Centre Similar oral... 
Via Benzinga
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs
Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV... 
Via Benzinga
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
From Gilead Sciences, Inc.
Via Business Wire
Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US
Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including... 
Via Benzinga
Former Clinician Alain Chan Finds Opportunity to Expand Impact, Develop Personally and Professionally
SOURCE: Gilead Sciences 
Via 3BL Media
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Developing Future Social Justice Leaders at Tougaloo College
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
7 Safe Stocks for Your Retirement
In a dynamic market like the one we're in now, it's important to buy safe stocks that will build your nest egg in the years to come. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Gilead Sciences
Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings wi... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Thursday
JP Morgan raised the price target for RPM International Inc. (NYSE: 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21
SOURCE: Gilead Sciences 
Via 3BL Media
Dogs of Major Indices
As we approach the end of 2021, we take a look at the ten Dow stocks that would currently make up the Dogs of the Dow for 2022. 
Via Talk Markets
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
Via Benzinga
NRXP Stock Alert: What Is Going on With NRx Pharmaceuticals Today?
NRx is seeking breakthrough designation for its treatment based on new, favorable data on the drug. NRXP stock is climbing on the news. 
Via InvestorPlace
Pfizer's CEO Shows You How To Get 'Impossible' Tasks Done Fast
Scientists told the Pfizer CEO they could create a vaccine in 18 months. But Albert Bourla knew they could work even faster. 
Via Investor's Business Daily
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Russian Foundation Provides Career Guidance for Teens Living With HIV
SOURCE: Gilead Sciences 
Via 3BL Media
Best Stocks For Wheel Strategy Trades: Use These In 2022
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy. 
Via Talk Markets
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
Gilead Sciences Inc (NASDAQ: GILD) announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
45 46 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.